Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03241641 |
|
Recruitment Status :
Completed
First Posted : August 7, 2017
Last Update Posted : March 29, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Treatment of CHB patients with genotypic resistance to NUCs has been problematic due to the lack of data from randomized trials. Recently, two randomized trials comparing the efficacy of TDF monotherapy versus TDF and ETV combination therapy in CHB patients with documented genotypic resistance to adefovir (ADV) or ETV demonstrated TDF monotherapy was not statistically different in viral suppression at week 48 of treatment.1,2 The extension study based on the above two trials merged study subjects from these trials with changing from TDF and ETV combination group to TDF monotherapy to evaluate long-term efficacy and safety of TDF monotherapy for multidrug-resistant patients. At the time of merging of 192 subjects, by intention-to-treat analysis, 66.3% of TDF group and 68.0% of TDF-ETV group had virological response as determined by serum HBV DNA <15 IU/mL. (in press) Three year long-term follow up study showed that the proportion of virologic suppression increased to 76.8% and 72.2% in TDF-TDF and TDF/TDF-ETV groups, respectively( P=0.46). (in press)
TAF, a novel prodrug of tenofovir was developed to have greater stability in plasma than TDF, thereby enabling more efficient delivery of the active metabolite to target cells at a substantially lower dose. The reduced systemic exposure of tenofovir offers the potential for an improved safety profile compared to TDF a benefit that demonstrated in a recent clinical trial in patients with HIV infection. In a recent double-blind randomized phase 3 noninferiority trial with 873 treatment naive patients who were positive for HBeAg, the proportion of patients receiving TAF who had HBV DNA <29 IU/mL at week 48 was 64%, which was non-inferior to the rate of 67% in patients receiving TDF (P=0.25).3 In the safety profile, TAF group had significantly smaller decrease in BMD than TDF group in the hip and spine, as well as significantly smaller increases in serum creatinine at week 48.3 For treatment naive HBeAg negative patients, a recent study with 425 subjects applied the same methodology and showed noninferiority in efficacy of TAF compared to TDF at week 48.4 Considering noninferiority in efficacy and superior bone and renal safety from TAF, TAF might be considered preferred choice of NUC instead of TDF. However, it is still unknown whether TAF would show similar efficacy and safety profile in patients with multidrug-resistant CHB.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Hepatitis b | Drug: Tenofovir Alafenamide Drug: Tenofovir Disoproxil Fumarate | Phase 4 |
Study objectives The objective of this study is to evaluate whether efficacy, safety, and tolerability (including bone and renal outcomes) were non-inferior in patients switched to a tenofovir alafenamide (TAF), compared with patients who remained on tenofovir disoproxil fumarate (TDF).
Study procedures This is a randomized, active-controlled, open-label, multicenter study to evaluate safety and non-inferior efficacy of switching from TDF 300 mg QD to TAF 25 mg QD for 48 weeks in chronic hepatitis B patients who have genotypic resistance to Adefovir/Entecavir.
174 subjects who complete the previous IN-US-174-0202/0205 studies will be randomized in a 1:1 ratio (A:B) to receive either TAF 25 mg QD or TDF 300 mg QD Case group: approximately 87 subjects administered TAF 25 mg QD Control group: approximately 87 subjects administered TDF 300 mg QD
The primary analysis will occur at Week 48 with the primary efficacy endpoint being newly achievement and maintenance of virologic response (HBV DNA <60 IU/mL at Week 48).
The duration of maintaining both arms is 48 weeks. All subjects who complete 48 weeks of treatment are eligible for participation in the open label TAF 25 mg extension period for an additional 48 weeks (through Week 96)
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 174 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Switching From Tenofovir Disoproxil Fumarate(TDF) to Tenofovir AlaFenamide(TAF) vs. Maintaining TDF Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir or Entecavir |
| Actual Study Start Date : | October 26, 2017 |
| Actual Primary Completion Date : | March 25, 2021 |
| Actual Study Completion Date : | March 25, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Maintaining TAF monotherapy
- Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 96 weeks
|
Drug: Tenofovir Alafenamide
25mg, Daily Oral
Other Name: Vemlidy |
Active Comparator: Switching from TDF to TAF
|
Drug: Tenofovir Alafenamide
25mg, Daily Oral
Other Name: Vemlidy Drug: Tenofovir Disoproxil Fumarate 300mg, Daily Oral
Other Name: Viread |
- Proportion of patients with virologic response [ Time Frame: At week 48 of treatment ]The proportion of patients who achieve virologic response (serum HBV DNA concentrations below 60 IU/mL)
- Proportion of patients with virologic response [ Time Frame: At week 96 of treatment ]The proportion of patients who achieve virologic response (serum HBV DNA concentrations below 60 IU/mL)
- The proportion of patients with HBV DNA less than 15 IU/mL [ Time Frame: At week 48, and 96 of treatment ]The proportion of patients with HBV DNA less than 15 IU/mL
- The proportion of patients with normal ALT [ Time Frame: At week 24, 48, 72 and 96 of treatment ]The proportion of patients with normal ALT
- The proportion of patients with HBeAg loss or seroconversion [ Time Frame: At week 24, 48, 72 and 96 of treatment ]The proportion of patients with HBeAg loss or seroconversion
- The proportion of patients with HBsAg loss or seroconversion [ Time Frame: At week 24, 48, 72 and 96 of treatment ]The proportion of patients with HBsAg loss or seroconversion
- The incidence of virologic breakthrough [ Time Frame: At week 48, and 96 of treatment ]Virologic breakthrough is defined as the increases in HBV DNA levels ≥1 log10IU/mL from nadir on two consecutive tests during continued treatment
- The proportion of patients with resistance mutations to Entecavir or Adefovir or Tenofovir [ Time Frame: At week 48, and 96 of treatment ]The proportion of patients with resistance mutations to Entecavir or Adefovir or Tenofovir
- Percentage change from baseline in hip and spine bone mineral density (BMD) [ Time Frame: At week 24, 48, 72 and 96 of treatment ]Percentage change from baseline in hip and spine bone mineral density (BMD)
- Percentage change from baseline in urine beta2-microglobulin [ Time Frame: At week 24, 48, 72 and 96 of treatment ]Percentage change from baseline in urine beta2-microglobulin
- Percentage change from baseline in urine protein to creatinine ratio [ Time Frame: At week 24, 48, 72 and 96 of treatment ]Percentage change from baseline in urine protein to creatinine ratio
- Percentage change from baseline in urine albumin to creatinine ratio [ Time Frame: At week 24, 48, 72 and 96 of treatment ]Percentage change from baseline in urine albumin to creatinine ratio
- Percentage change from baseline in serum creatinine [ Time Frame: At week 24, 48, 72 and 96 of treatment ]Percentage change from baseline in serum creatinine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 20 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:All of below
- Patient must have the ability to understand and sign a written informed consent form; consent must be obtained prior to initiation of study procedures
- Male or female, 20 to 80 years of age
- Compensated liver disease (Child-Pugh score < 8)
- HBsAg positive at least 6 months or more
- HBeAg positive or negative
- Confirmation of ETV resistance mutation (rt184, rtS202, or rtM250) at the enrollment of IN-US-174-0202 study, or ADV resistance mutation (rtA181V, rtA181T or rtN236T) at the enrollment of IN-US-174-0205 study
- Completion of the week 240 visit in studies IN-US-174-0202 or 0205 study and maintained on TDF 300 mg QD
- Patient is willing and able to comply with all study requirements
Exclusion Criteria: Any of below
- Co-infection with HCV, HDV, HIV
- Abusing alcohol (more than 40 g/day) or illicit drugs
- Abnormal hematological and biochemical parameters, including:
1) serum bilirubin >3 mg/dL 2) prothrombin time (INR) >1.5 3) serum albumin <2.8 g/dL 4) ascites, encephalopathy or variceal hemorrhage 5) Child-Pugh score ≥8
4. Received interferon or other immunomodulatory treatment for HBV infection in the 12 months before screening for this study
5. Medical condition that requires concurrent use of systemic corticosteroid or other immunosuppressive agent
6. Received solid organ or bone marrow transplant
7. Known hypersensitivity to study drugs, metabolites, or formulation excipients
8. Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the patient unsuitable for the study or unable to comply with dosing requirements
9. Use of investigational agents within 3 months of screening, unless allowed by the Sponsor or Investigator
10. A history of hepatocellular carcinoma (HCC) within 5 years of screening
11. A history treated malignancy (other than HCC) is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding three years
12. Participation in another investigational drug trial
13. Pregnant or breastfeeding or willing to be pregnant
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03241641
| Korea, Republic of | |
| Asan Medical Center | |
| Seoul, Korea, Republic of, 05505 | |
| Principal Investigator: | Young-Suk Lim, M.D.,Ph D. | Asan Medical Center |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Young-Suk Lim, Professor, Asan Medical Center |
| ClinicalTrials.gov Identifier: | NCT03241641 |
| Other Study ID Numbers: |
IN-US-320-4390 |
| First Posted: | August 7, 2017 Key Record Dates |
| Last Update Posted: | March 29, 2021 |
| Last Verified: | March 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Hepatitis A Hepatitis B Hepatitis B, Chronic Hepatitis Hepatitis, Chronic Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Infections Enterovirus Infections Picornaviridae Infections RNA Virus Infections |
Blood-Borne Infections Communicable Diseases Hepadnaviridae Infections DNA Virus Infections Tenofovir Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents |